vasopharm is a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebrovascular diseases.
Location: Germany, Bavaria, Würzburg
Employees: 11-50
Total raised: $35.55M
Founded date: 1998
Investors 3
Funding Rounds 2
| Date | Series | Amount | Investors |
| 11.07.2019 | - | $11.45M | - |
| 21.01.2016 | - | $24.1M | - |
Mentions in press and media 9
| Date | Title | Description |
| 11.07.2019 | Daily funding roundup - July 11th, 2019 | Swit raised $6M; GetAccept landed $7M; DMC closed $10.3M; NEAR secured $12.1M Swit: Swit is a collaboration suite that promises freedom from integrations. Swit has raised $6 million in seed funding. Korea Investment Partners led the round, ... |
| 11.07.2019 | German biotech company vasopharm raises €9.5 million to commercialize its treatment for traumatic brain injuries | It’s likely you’ve hit your head before and thought nothing of it. But depending on the severity of the impact, it could result in a traumatic brain injury (TBI) – a common, underdiagnosed condition that can result in a range of cognitive a... |
| 11.07.2019 | vasopharm Closes €9.5M Financing Round | vasopharm GmbH, a Wurzburg, Germany-based private biopharmaceutical company developing a novel treatment for traumatic brain injury (TBI), closed a €9.5m financing. The round was co-led by HeidelbergCapital Private Equity and EF Investments... |
| 21.01.2016 | vasopharm Raises €20M in Funding | vasopharm GmbH, a Wuerzburg, Germany-based biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, raised €20m in funding. The round was co-led by existing investors Entrepreneurs Fund, Heidel... |
| 21.01.2016 | Daily funding roundup - January 21, 2016 | Canvs secured $5.6M; KTB Network led $4.5M funding for Qeexo; Arrayent landed additional $4M funding Arrayent announced that it has raised an additional $4 million in Series C funding from ORIX Ventures, adding to the initial $11 million it... |
| - | vasopharm closes €9.5 million Financing Round | vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury (TBI), today announced the successful completion of a € 9.5 million financing co-led by HeidelbergCapital Private Equity and EF Inve... |
| - | #MakeItTen: Interview with vasopharm | Make It Ten №5 is with Christian Wandersee, CEO of the most recent investment of our CV IV fund: vasopharm. Hopefully, as a private person, you will never have to deal with the product vasopharm is developing, but if you do, it might save y... |
| - | vasopharm closes €20M fundraising | Würzburg, Germany – January 21, 2016 – vasopharm GmbH, a privately held biopharmaceutical company focusing on novel therapeutics for the treatment of cerebrovascular diseases, today announced it has successfully raised EUR 20 million of new... |
| - | vasopharm Closes € 9.5 million Financing Round | Würzburg, Germany – July 11, 2019: vasopharm GmbH, a private biopharmaceutical company developing a novel treatment for traumatic brain injury (TBI), today announced the successful completion of a €9.5 million financing co-led by Heidelberg... |